Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice

Selma Alin Somilleda-Ventura; Ruth Mery López-Mayorga; Eduardo Meaney-Mendiolea; Angel Ivan Orlando Rubio-Gayosso; Héctor Javier Pérez-Cano; Guillermo Manuel Ceballos-Reyes; Virgilio Lima-Gómez

doi:10.1016/j.jneuroim.2023.578018

Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice

Selma Alin Somilleda-Ventura, Ruth Mery López-Mayorga, Eduardo Meaney-Mendiolea, Angel Ivan Orlando Rubio-Gayosso, Héctor Javier Pérez-Cano, Guillermo Manuel Ceballos-Reyes, Virgilio Lima-Gómez

Research output: Contribution to journal › Article › peer-review

Abstract

Our objective was to determine whether (-)-Epicatechin administered alone or simultaneously with topical Ketorolac decreased the relative expression of GFAP and modulated the response of Nrf2 in a mouse model with induced hyperglycemia. We found that GFAP and Nrf2 decreased in the groups that received treatments alone or simultaneous during 8 weeks; even when the effect on the Nrf2 was not pronounced, it showed a higher concentration when GFAP decreased. Our results suggest a protective effect of Ketorolac and (-) - Epicatechin, which seem to limit the preclinical retinal damage caused by inflammation in hyperglycemia.

Original language	English
Article number	578018
Journal	Journal of Neuroimmunology
Volume	375
DOIs	https://doi.org/10.1016/j.jneuroim.2023.578018
State	Published - 15 Feb 2023

Keywords

GFAP
Hyperglycemia
Microglia
NRF2
Neural damage
Retinal damage

Access to Document

10.1016/j.jneuroim.2023.578018

Cite this

@article{0078a71fa0c240e19f1c67d893cfbbe8,

title = "Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice",

abstract = "Our objective was to determine whether (-)-Epicatechin administered alone or simultaneously with topical Ketorolac decreased the relative expression of GFAP and modulated the response of Nrf2 in a mouse model with induced hyperglycemia. We found that GFAP and Nrf2 decreased in the groups that received treatments alone or simultaneous during 8 weeks; even when the effect on the Nrf2 was not pronounced, it showed a higher concentration when GFAP decreased. Our results suggest a protective effect of Ketorolac and (-) - Epicatechin, which seem to limit the preclinical retinal damage caused by inflammation in hyperglycemia.",

keywords = "GFAP, Hyperglycemia, Microglia, NRF2, Neural damage, Retinal damage",

author = "Somilleda-Ventura, {Selma Alin} and L{\'o}pez-Mayorga, {Ruth Mery} and Eduardo Meaney-Mendiolea and Rubio-Gayosso, {Angel Ivan Orlando} and P{\'e}rez-Cano, {H{\'e}ctor Javier} and Ceballos-Reyes, {Guillermo Manuel} and Virgilio Lima-G{\'o}mez",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = feb,

day = "15",

doi = "10.1016/j.jneuroim.2023.578018",

language = "Ingl{\'e}s",

volume = "375",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

}

TY - JOUR

T1 - Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice

AU - Somilleda-Ventura, Selma Alin

AU - López-Mayorga, Ruth Mery

AU - Meaney-Mendiolea, Eduardo

AU - Rubio-Gayosso, Angel Ivan Orlando

AU - Pérez-Cano, Héctor Javier

AU - Ceballos-Reyes, Guillermo Manuel

AU - Lima-Gómez, Virgilio

PY - 2023/2/15

Y1 - 2023/2/15

N2 - Our objective was to determine whether (-)-Epicatechin administered alone or simultaneously with topical Ketorolac decreased the relative expression of GFAP and modulated the response of Nrf2 in a mouse model with induced hyperglycemia. We found that GFAP and Nrf2 decreased in the groups that received treatments alone or simultaneous during 8 weeks; even when the effect on the Nrf2 was not pronounced, it showed a higher concentration when GFAP decreased. Our results suggest a protective effect of Ketorolac and (-) - Epicatechin, which seem to limit the preclinical retinal damage caused by inflammation in hyperglycemia.

AB - Our objective was to determine whether (-)-Epicatechin administered alone or simultaneously with topical Ketorolac decreased the relative expression of GFAP and modulated the response of Nrf2 in a mouse model with induced hyperglycemia. We found that GFAP and Nrf2 decreased in the groups that received treatments alone or simultaneous during 8 weeks; even when the effect on the Nrf2 was not pronounced, it showed a higher concentration when GFAP decreased. Our results suggest a protective effect of Ketorolac and (-) - Epicatechin, which seem to limit the preclinical retinal damage caused by inflammation in hyperglycemia.

KW - GFAP

KW - Hyperglycemia

KW - Microglia

KW - NRF2

KW - Neural damage

KW - Retinal damage

UR - http://www.scopus.com/inward/record.url?scp=85146480317&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2023.578018

DO - 10.1016/j.jneuroim.2023.578018

M3 - Artículo

C2 - 36657373

AN - SCOPUS:85146480317

SN - 0165-5728

VL - 375

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 578018

ER -

Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this